



## Clinical trial results:

**A Phase II, non-randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted (pre-) pandemic H5N1 influenza candidate vaccine following a heterologous prime-boost schedule (six months apart) in children aged 6 to 35 months.**

### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2011-004734-33   |
| Trial protocol           | Outside EU/EEA   |
| Global end of trial date | 02 November 2012 |

### Results information

|                                |             |
|--------------------------------|-------------|
| Result version number          | v1          |
| This version publication date  | 13 May 2016 |
| First version publication date | 24 May 2015 |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 109825 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT01323946 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |                                                                                                        |
|------------------------------|--------------------------------------------------------------------------------------------------------|
| Sponsor organisation name    | GlaxoSmithKline Biologicals                                                                            |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330                                                       |
| Public contact               | Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 044 2089904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact           | Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 044 2089904466, GSKClinicalSupportHD@gsk.com |

Notes:

### Paediatric regulatory details

|                                                                      |                     |
|----------------------------------------------------------------------|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP)       | Yes                 |
| EMA paediatric investigation plan number(s)                          | EMA-000160-PIP01-07 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No                  |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes                 |

Notes:

## Results analysis stage

|                                                      |                  |
|------------------------------------------------------|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 14 February 2013 |
| Is this the analysis of the primary completion data? | Yes              |
| Primary completion date                              | 22 June 2012     |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 02 November 2012 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

To assess whether a heterologous booster dose of H5N1 (A/turkey/Turkey/1/2005) haemagglutinin (HA) given 6 months following a 2-dose primary vaccination series with H5N1 (A/Indonesia/05/2005) HA elicits an antibody response that meets the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) guidance targets for pre-pandemic vaccine seroconversion rate (SCR)\*, seroprotection rate (SPR)\* and mean geometric increase (MGI)\* based on haemagglutination inhibition (HI) responses to A/turkey/Turkey/1/2005 (H5N1) ten days following booster vaccination.

Protection of trial subjects:

Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines.

Background therapy: -

Evidence for comparator: -

|                                                           |               |
|-----------------------------------------------------------|---------------|
| Actual start date of recruitment                          | 18 April 2011 |
| Long term follow-up planned                               | No            |
| Independent data monitoring committee (IDMC) involvement? | No            |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |               |
|--------------------------------------|---------------|
| Country: Number of subjects enrolled | Australia: 29 |
| Country: Number of subjects enrolled | Singapore: 84 |
| Worldwide total number of subjects   | 113           |
| EEA total number of subjects         | 0             |

Notes:

### Subjects enrolled per age group

|                                           |    |
|-------------------------------------------|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 80 |
| Children (2-11 years)                     | 33 |
| Adolescents (12-17 years)                 | 0  |
| Adults (18-64 years)                      | 0  |
| From 65 to 84 years                       | 0  |

|                   |   |
|-------------------|---|
| 85 years and over | 0 |
|-------------------|---|

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

### Period 1

|                              |                             |
|------------------------------|-----------------------------|
| Period 1 title               | Overall (overall period)    |
| Is this the baseline period? | Yes                         |
| Allocation method            | Non-randomised - controlled |
| Blinding used                | Not blinded                 |

### Arms

|                              |                          |
|------------------------------|--------------------------|
| Are arms mutually exclusive? | Yes                      |
| <b>Arm title</b>             | GSK1562902A 6<12 M Group |

Arm description:

Subjects between 6 and 12 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

|                                        |                     |
|----------------------------------------|---------------------|
| Arm type                               | Experimental        |
| Investigational medicinal product name | GSK1562902A vaccine |
| Investigational medicinal product code |                     |
| Other name                             |                     |
| Pharmaceutical forms                   | Injection           |
| Routes of administration               | Intramuscular use   |

Dosage and administration details:

The vaccine was administered intramuscularly in the anterolateral thigh

|                  |                           |
|------------------|---------------------------|
| <b>Arm title</b> | GSK1562902A 12<24 M Group |
|------------------|---------------------------|

Arm description:

Subjects between 12 and 24 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

|                                        |                     |
|----------------------------------------|---------------------|
| Arm type                               | Experimental        |
| Investigational medicinal product name | GSK1562902A vaccine |
| Investigational medicinal product code |                     |
| Other name                             |                     |
| Pharmaceutical forms                   | Injection           |
| Routes of administration               | Intramuscular use   |

Dosage and administration details:

The vaccine was administered intramuscularly in the deltoid region of arm

|                                        |                     |
|----------------------------------------|---------------------|
| Investigational medicinal product name | GSK1562902A vaccine |
| Investigational medicinal product code |                     |
| Other name                             |                     |
| Pharmaceutical forms                   | Injection           |
| Routes of administration               | Intramuscular use   |

Dosage and administration details:

The vaccine was administered intramuscularly in the deltoid region of arm

|                  |                           |
|------------------|---------------------------|
| <b>Arm title</b> | GSK1562902A 24<36 M Group |
|------------------|---------------------------|

---

**Arm description:**

Subjects between 24 and 36 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

|                                        |                     |
|----------------------------------------|---------------------|
| Arm type                               | Experimental        |
| Investigational medicinal product name | GSK1562902A vaccine |
| Investigational medicinal product code |                     |
| Other name                             |                     |
| Pharmaceutical forms                   | Injection           |
| Routes of administration               | Intramuscular use   |

**Dosage and administration details:**

The vaccine was administered intramuscularly in the deltoid region of arm

| <b>Number of subjects in period 1</b> | GSK1562902A 6<12 M Group | GSK1562902A 12<24 M Group | GSK1562902A 24<36 M Group |
|---------------------------------------|--------------------------|---------------------------|---------------------------|
| Started                               | 46                       | 34                        | 33                        |
| Completed                             | 43                       | 31                        | 33                        |
| Not completed                         | 3                        | 3                         | 0                         |
| Consent withdrawn by subject          | 3                        | 3                         | -                         |

## Baseline characteristics

### Reporting groups

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | GSK1562902A 6<12 M Group |
|-----------------------|--------------------------|

Reporting group description:

Subjects between 6 and 12 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | GSK1562902A 12<24 M Group |
|-----------------------|---------------------------|

Reporting group description:

Subjects between 12 and 24 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | GSK1562902A 24<36 M Group |
|-----------------------|---------------------------|

Reporting group description:

Subjects between 24 and 36 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

| Reporting group values                                                                                                                                                                                                                                    | GSK1562902A 6<12 M Group | GSK1562902A 12<24 M Group | GSK1562902A 24<36 M Group |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------|---------------------------|
| Number of subjects                                                                                                                                                                                                                                        | 46                       | 34                        | 33                        |
| Age categorical<br>Units: Subjects                                                                                                                                                                                                                        |                          |                           |                           |
| In utero<br>Preterm newborn infants (gestational age < 37 wks)<br>Newborns (0-27 days)<br>Infants and toddlers (28 days-23 months)<br>Children (2-11 years)<br>Adolescents (12-17 years)<br>Adults (18-64 years)<br>From 65-84 years<br>85 years and over |                          |                           |                           |
| Age continuous<br>Units: months                                                                                                                                                                                                                           |                          |                           |                           |
| arithmetic mean                                                                                                                                                                                                                                           | 8.3                      | 16.1                      | 29.6                      |
| standard deviation                                                                                                                                                                                                                                        | ± 1.56                   | ± 3.44                    | ± 3.38                    |
| Gender categorical<br>Units: Subjects                                                                                                                                                                                                                     |                          |                           |                           |
| Female                                                                                                                                                                                                                                                    | 25                       | 19                        | 19                        |
| Male                                                                                                                                                                                                                                                      | 21                       | 15                        | 14                        |

| Reporting group values                                                                 | Total       |  |  |
|----------------------------------------------------------------------------------------|-------------|--|--|
| Number of subjects                                                                     | 113         |  |  |
| Age categorical<br>Units: Subjects                                                     |             |  |  |
| In utero<br>Preterm newborn infants (gestational age < 37 wks)<br>Newborns (0-27 days) | 0<br>0<br>0 |  |  |

|                                                                          |    |  |  |
|--------------------------------------------------------------------------|----|--|--|
| Infants and toddlers (28 days-23 months)                                 | 0  |  |  |
| Children (2-11 years)                                                    | 0  |  |  |
| Adolescents (12-17 years)                                                | 0  |  |  |
| Adults (18-64 years)                                                     | 0  |  |  |
| From 65-84 years                                                         | 0  |  |  |
| 85 years and over                                                        | 0  |  |  |
| Age continuous<br>Units: months<br>arithmetic mean<br>standard deviation | -  |  |  |
| Gender categorical<br>Units: Subjects                                    |    |  |  |
| Female                                                                   | 63 |  |  |
| Male                                                                     | 50 |  |  |

### Subject analysis sets

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | GSK1562902A Group  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Subjects received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

| Reporting group values                                                                                                                                                                                                                                    | GSK1562902A Group |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--|--|
| Number of subjects                                                                                                                                                                                                                                        | 113               |  |  |
| Age categorical<br>Units: Subjects                                                                                                                                                                                                                        |                   |  |  |
| In utero<br>Preterm newborn infants (gestational age < 37 wks)<br>Newborns (0-27 days)<br>Infants and toddlers (28 days-23 months)<br>Children (2-11 years)<br>Adolescents (12-17 years)<br>Adults (18-64 years)<br>From 65-84 years<br>85 years and over |                   |  |  |
| Age continuous<br>Units: months<br>arithmetic mean<br>standard deviation                                                                                                                                                                                  | 16.9<br>± 9.29    |  |  |
| Gender categorical<br>Units: Subjects                                                                                                                                                                                                                     |                   |  |  |
| Female                                                                                                                                                                                                                                                    | 63                |  |  |
| Male                                                                                                                                                                                                                                                      | 50                |  |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                       |                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Reporting group title                                                                                                                                                                                                                 | GSK1562902A 6<12 M Group  |
| Reporting group description:<br>Subjects between 6 and 12 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.  |                           |
| Reporting group title                                                                                                                                                                                                                 | GSK1562902A 12<24 M Group |
| Reporting group description:<br>Subjects between 12 and 24 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182. |                           |
| Reporting group title                                                                                                                                                                                                                 | GSK1562902A 24<36 M Group |
| Reporting group description:<br>Subjects between 24 and 36 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182. |                           |
| Subject analysis set title                                                                                                                                                                                                            | GSK1562902A Group         |
| Subject analysis set type                                                                                                                                                                                                             | Sub-group analysis        |
| Subject analysis set description:<br>Subjects received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.                                 |                           |

### Primary: Number of seroconverted subjects in terms of HI antibodies

|                                                                                     |                                                                           |
|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| End point title                                                                     | Number of seroconverted subjects in terms of HI antibodies <sup>[1]</sup> |
| End point description:<br>HI antibody concentration against A/turkey/Turkey/01/2005 |                                                                           |
| End point type                                                                      | Primary                                                                   |
| End point timeframe:<br>At Day 192                                                  |                                                                           |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.

|                                      |                      |  |  |  |
|--------------------------------------|----------------------|--|--|--|
| <b>End point values</b>              | GSK1562902A Group    |  |  |  |
| Subject group type                   | Subject analysis set |  |  |  |
| Number of subjects analysed          | 83                   |  |  |  |
| Units: Subjects                      |                      |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 192] | 83                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Geometric mean of the within-subject ratios

|                                                                                     |                                                            |
|-------------------------------------------------------------------------------------|------------------------------------------------------------|
| End point title                                                                     | Geometric mean of the within-subject ratios <sup>[2]</sup> |
| End point description:<br>HI antibody concentration against Flu A/Turk/01/05 (H5N1) |                                                            |

|                                                                                                                                                                     |         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| End point type                                                                                                                                                      | Primary |
| End point timeframe:                                                                                                                                                |         |
| At Day 192                                                                                                                                                          |         |
| Notes:                                                                                                                                                              |         |
| [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. |         |
| Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.                                                          |         |

|                                          |                        |  |  |  |
|------------------------------------------|------------------------|--|--|--|
| <b>End point values</b>                  | GSK1562902A Group      |  |  |  |
| Subject group type                       | Subject analysis set   |  |  |  |
| Number of subjects analysed              | 83                     |  |  |  |
| Units: Titers                            |                        |  |  |  |
| geometric mean (confidence interval 95%) |                        |  |  |  |
| Flu A/Turk/01/05 (H5N1).HA [Day 192]     | 357.7 (302.4 to 423.2) |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of seroprotected subjects for HI antibodies

|                                                                                                                                                                     |                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| End point title                                                                                                                                                     | Number of seroprotected subjects for HI antibodies <sup>[3]</sup> |
| End point description:                                                                                                                                              |                                                                   |
| HI antibody concentration against A/turkey/Turkey/01/2005                                                                                                           |                                                                   |
| End point type                                                                                                                                                      | Primary                                                           |
| End point timeframe:                                                                                                                                                |                                                                   |
| At Day 192                                                                                                                                                          |                                                                   |
| Notes:                                                                                                                                                              |                                                                   |
| [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. |                                                                   |
| Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.                                                          |                                                                   |

|                                     |                      |  |  |  |
|-------------------------------------|----------------------|--|--|--|
| <b>End point values</b>             | GSK1562902A Group    |  |  |  |
| Subject group type                  | Subject analysis set |  |  |  |
| Number of subjects analysed         | 83                   |  |  |  |
| Units: Subjects                     |                      |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day192] | 83                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: HI antibody titers

|                                                       |                    |
|-------------------------------------------------------|--------------------|
| End point title                                       | HI antibody titers |
| End point description:                                |                    |
| HI antibody concentration against A/Indonezia/05/2005 |                    |

|                                                |           |
|------------------------------------------------|-----------|
| End point type                                 | Secondary |
| End point timeframe:                           |           |
| At Day 0, Day 42, Day 182, Day 192 and Day 364 |           |

|                                          |                           |  |  |  |
|------------------------------------------|---------------------------|--|--|--|
| <b>End point values</b>                  | GSK1562902A Group         |  |  |  |
| Subject group type                       | Subject analysis set      |  |  |  |
| Number of subjects analysed              | 100                       |  |  |  |
| Units: Titers                            |                           |  |  |  |
| geometric mean (confidence interval 95%) |                           |  |  |  |
| A/Indonesia/05/2005.HA [Day 0]           | 5 (5 to 5)                |  |  |  |
| A/Indonesia/05/2005.HA [Day 42]          | 1078.6 (935.3 to 1243.7)  |  |  |  |
| A/Indonesia/05/2005.HA [Day 182]         | 147.2 (129.6 to 167.1)    |  |  |  |
| A/Indonesia/05/2005.HA [Day 192]         | 1787.6 (1552.4 to 2058.3) |  |  |  |
| A/Indonesia/05/2005.HA [Day 364]         | 1043.3 (886.1 to 1228.4)  |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: HI antibody titers

|                                                           |                    |
|-----------------------------------------------------------|--------------------|
| End point title                                           | HI antibody titers |
| End point description:                                    |                    |
| HI antibody concentration against A/turkey/Turkey/01/2005 |                    |
| End point type                                            | Secondary          |
| End point timeframe:                                      |                    |
| At Day 0, Day 182, Day 192 and Day 364                    |                    |

|                                          |                           |  |  |  |
|------------------------------------------|---------------------------|--|--|--|
| <b>End point values</b>                  | GSK1562902A Group         |  |  |  |
| Subject group type                       | Subject analysis set      |  |  |  |
| Number of subjects analysed              | 100                       |  |  |  |
| Units: Titers                            |                           |  |  |  |
| geometric mean (confidence interval 95%) |                           |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 0]       | 5.7 (5.2 to 6.2)          |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 182]     | 89.3 (79.1 to 100.7)      |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 192]     | 2026.2 (1731.3 to 2371.3) |  |  |  |

|                                      |                         |  |  |  |
|--------------------------------------|-------------------------|--|--|--|
| A/turkey/Turkey/01/2005.HA [Day 364] | 1266.8 (1080.6 to 1485) |  |  |  |
|--------------------------------------|-------------------------|--|--|--|

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with anti-HIs antibody concentrations $\geq$ 1:10

|                                                                                 |                                                                      |
|---------------------------------------------------------------------------------|----------------------------------------------------------------------|
| End point title                                                                 | Number of subjects with anti-HIs antibody concentrations $\geq$ 1:10 |
| End point description:<br>HI antibody concentration against A/Indonezia/05/2005 |                                                                      |
| End point type                                                                  | Secondary                                                            |
| End point timeframe:<br>At Day 0, Day 42, Day 182, Day 192 and Day 364          |                                                                      |

| End point values                 | GSK1562902A Group    |  |  |  |
|----------------------------------|----------------------|--|--|--|
| Subject group type               | Subject analysis set |  |  |  |
| Number of subjects analysed      | 100                  |  |  |  |
| Units: Subjects                  |                      |  |  |  |
| A/Indonesia/05/2005.HA [Day 0]   | 0                    |  |  |  |
| A/Indonesia/05/2005.HA [Day 42]  | 85                   |  |  |  |
| A/Indonesia/05/2005.HA [Day 182] | 83                   |  |  |  |
| A/Indonesia/05/2005.HA [Day 192] | 83                   |  |  |  |
| A/Indonesia/05/2005.HA [Day 364] | 100                  |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with anti-HIs antibody concentrations $\geq$ 1:10

|                                                                                     |                                                                      |
|-------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| End point title                                                                     | Number of subjects with anti-HIs antibody concentrations $\geq$ 1:10 |
| End point description:<br>HI antibody concentration against A/turkey/Turkey/01/2005 |                                                                      |
| End point type                                                                      | Secondary                                                            |
| End point timeframe:<br>At Day 0, Day 182, Day 192 and Day 364                      |                                                                      |

|                                      |                      |  |  |  |
|--------------------------------------|----------------------|--|--|--|
| <b>End point values</b>              | GSK1562902A Group    |  |  |  |
| Subject group type                   | Subject analysis set |  |  |  |
| Number of subjects analysed          | 100                  |  |  |  |
| Units: Subjects                      |                      |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 0]   | 11                   |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 182] | 83                   |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 192] | 83                   |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 364] | 100                  |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroconverted subjects in terms of HI antibodies

|                        |                                                            |
|------------------------|------------------------------------------------------------|
| End point title        | Number of seroconverted subjects in terms of HI antibodies |
| End point description: | HI antibody concentration against A/Indonesia/05/2005      |
| End point type         | Secondary                                                  |
| End point timeframe:   | At Day 42, Day 182, Day 192 and Day 364                    |

|                                  |                      |  |  |  |
|----------------------------------|----------------------|--|--|--|
| <b>End point values</b>          | GSK1562902A Group    |  |  |  |
| Subject group type               | Subject analysis set |  |  |  |
| Number of subjects analysed      | 100                  |  |  |  |
| Units: Subjects                  |                      |  |  |  |
| A/Indonesia/05/2005.HA [Day 42]  | 85                   |  |  |  |
| A/Indonesia/05/2005.HA [Day 182] | 83                   |  |  |  |
| A/Indonesia/05/2005.HA [Day 192] | 83                   |  |  |  |
| A/Indonesia/05/2005.HA [Day 364] | 100                  |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroconverted subjects in terms of HI antibodies

|                        |                                                            |
|------------------------|------------------------------------------------------------|
| End point title        | Number of seroconverted subjects in terms of HI antibodies |
| End point description: | HI antibody concentration against Flu A/Turk/01/05 (H5N1)  |
| End point type         | Secondary                                                  |
| End point timeframe:   | At Day 364                                                 |

|                                      |                      |  |  |  |
|--------------------------------------|----------------------|--|--|--|
| <b>End point values</b>              | GSK1562902A Group    |  |  |  |
| Subject group type                   | Subject analysis set |  |  |  |
| Number of subjects analysed          | 99                   |  |  |  |
| Units: Subjects                      |                      |  |  |  |
| Flu A/Turk/01/05 (H5N1).HA [Day 364] | 95                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroprotected subjects for HI antibodies

|                        |                                                    |
|------------------------|----------------------------------------------------|
| End point title        | Number of seroprotected subjects for HI antibodies |
| End point description: |                                                    |
| End point type         | Secondary                                          |
| End point timeframe:   |                                                    |
| At Day 0 and Day 364   |                                                    |

|                                      |                      |  |  |  |
|--------------------------------------|----------------------|--|--|--|
| <b>End point values</b>              | GSK1562902A Group    |  |  |  |
| Subject group type                   | Subject analysis set |  |  |  |
| Number of subjects analysed          | 100                  |  |  |  |
| Units: Subjects                      |                      |  |  |  |
| Flu A/Ind/05/05 (H5N1).HA [Day 0]    | 0                    |  |  |  |
| Flu A/Ind/05/05 (H5N1).HA [Day 364]  | 100                  |  |  |  |
| Flu A/Turk/01/05 (H5N1).HA [Day 0]   | 1                    |  |  |  |
| Flu A/Turk/01/05 (H5N1).HA [Day 364] | 100                  |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Geometric mean of the within-subject ratios for the assessed H5N1 strains

|                        |                                                                           |
|------------------------|---------------------------------------------------------------------------|
| End point title        | Geometric mean of the within-subject ratios for the assessed H5N1 strains |
| End point description: |                                                                           |
| End point type         | Secondary                                                                 |

End point timeframe:

At Day 364

|                                          |                        |  |  |  |
|------------------------------------------|------------------------|--|--|--|
| <b>End point values</b>                  | GSK1562902A Group      |  |  |  |
| Subject group type                       | Subject analysis set   |  |  |  |
| Number of subjects analysed              | 100                    |  |  |  |
| Units: Titers                            |                        |  |  |  |
| geometric mean (confidence interval 95%) |                        |  |  |  |
| Flu A/Ind/05/05 (H5N1).HA [Day 364]      | 208.7 (177.2 to 245.7) |  |  |  |
| Flu A/Turk/01/05 (H5N1).HA [Day 364]     | 14.9 (12.6 to 17.6)    |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroconverted subjects in terms of HI antibodies

|                 |                                                            |
|-----------------|------------------------------------------------------------|
| End point title | Number of seroconverted subjects in terms of HI antibodies |
|-----------------|------------------------------------------------------------|

End point description:

HI antibody concentration against A/turkey/Turkey/01/2005.HA

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 192 and Day 364

|                                      |                      |  |  |  |
|--------------------------------------|----------------------|--|--|--|
| <b>End point values</b>              | GSK1562902A Group    |  |  |  |
| Subject group type                   | Subject analysis set |  |  |  |
| Number of subjects analysed          | 99                   |  |  |  |
| Units: Subjects                      |                      |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 192] | 82                   |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 364] | 95                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Factor

|                 |                |
|-----------------|----------------|
| End point title | Booster Factor |
|-----------------|----------------|

End point description:

Booster Factor was defined as the geometric mean of the within-subject ratios of the post-booster

vaccination reciprocal HI titre to the pre-booster (Day 182) reciprocal titre.

|                        |           |
|------------------------|-----------|
| End point type         | Secondary |
| End point timeframe:   |           |
| At Day 192 and Day 364 |           |

|                                          |                      |  |  |  |
|------------------------------------------|----------------------|--|--|--|
| <b>End point values</b>                  | GSK1562902A Group    |  |  |  |
| Subject group type                       | Subject analysis set |  |  |  |
| Number of subjects analysed              | 99                   |  |  |  |
| Units: Titers                            |                      |  |  |  |
| geometric mean (confidence interval 95%) |                      |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 192]     | 22.7 (19.3 to 26.8)  |  |  |  |
| A/turkey/Turkey/01/2005.HA [Day 364]     | 14.9 (12.6 to 17.6)  |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with serum neutralising antibody titers $\geq$ 1:28

|                                                          |                                                                        |
|----------------------------------------------------------|------------------------------------------------------------------------|
| End point title                                          | Number of subjects with serum neutralising antibody titers $\geq$ 1:28 |
| End point description:                                   |                                                                        |
| HI antibody concentration against Flu A/Ind/05/05 (H5N1) |                                                                        |
| End point type                                           | Secondary                                                              |
| End point timeframe:                                     |                                                                        |
| Day 0, Day 42, Day 182, Day 192 and Day 364              |                                                                        |

|                                  |                      |  |  |  |
|----------------------------------|----------------------|--|--|--|
| <b>End point values</b>          | GSK1562902A Group    |  |  |  |
| Subject group type               | Subject analysis set |  |  |  |
| Number of subjects analysed      | 95                   |  |  |  |
| Units: Subjects                  |                      |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 0]   | 1                    |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 42]  | 70                   |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 182] | 81                   |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 192] | 83                   |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 364] | 95                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with serum neutralising antibody titers $\geq$ 1:28

|                 |                                                                        |
|-----------------|------------------------------------------------------------------------|
| End point title | Number of subjects with serum neutralising antibody titers $\geq$ 1:28 |
|-----------------|------------------------------------------------------------------------|

End point description:

HI antibody concentration against Flu A/Turk/01/05 (H5N1)

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 0, Day 182, Day 192 and Day 364

|                                   |                      |  |  |  |
|-----------------------------------|----------------------|--|--|--|
| <b>End point values</b>           | GSK1562902A Group    |  |  |  |
| Subject group type                | Subject analysis set |  |  |  |
| Number of subjects analysed       | 95                   |  |  |  |
| Units: Subjects                   |                      |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 0]   | 0                    |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 182] | 81                   |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 192] | 83                   |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 364] | 95                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum neutralising antibody titres

|                 |                                    |
|-----------------|------------------------------------|
| End point title | Serum neutralising antibody titres |
|-----------------|------------------------------------|

End point description:

Antibody titers against Flu A/Ind/05/05 (H5N1)

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 0, Day 42, Day 182, Day 192 and Day 364

|                                          |                       |  |  |  |
|------------------------------------------|-----------------------|--|--|--|
| <b>End point values</b>                  | GSK1562902A Group     |  |  |  |
| Subject group type                       | Subject analysis set  |  |  |  |
| Number of subjects analysed              | 95                    |  |  |  |
| Units: Titers                            |                       |  |  |  |
| geometric mean (confidence interval 95%) |                       |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 0]           | 14.1 (13.9 to 14.4)   |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 42]          | 1858 (1491.3 to 2315) |  |  |  |

|                                  |                             |  |  |  |
|----------------------------------|-----------------------------|--|--|--|
| Flu A/Ind/05/05 (H5N1) [Day 182] | 448.7 (379 to 531.2)        |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 192] | 11215.7 (9797.4 to 12839.2) |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 364] | 4283.3 (3485.8 to 5263.2)   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum neutralising antibody titres

|                                                                                     |                                    |
|-------------------------------------------------------------------------------------|------------------------------------|
| End point title                                                                     | Serum neutralising antibody titres |
| End point description:<br>HI antibody concentration against Flu A/Turk/01/05 (H5N1) |                                    |
| End point type                                                                      | Secondary                          |
| End point timeframe:<br>Day 0, Day 182, Day 192 and Day 364                         |                                    |

|                                          |                           |  |  |  |
|------------------------------------------|---------------------------|--|--|--|
| <b>End point values</b>                  | GSK1562902A Group         |  |  |  |
| Subject group type                       | Subject analysis set      |  |  |  |
| Number of subjects analysed              | 95                        |  |  |  |
| Units: Titers                            |                           |  |  |  |
| geometric mean (confidence interval 95%) |                           |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 0]          | 14 (14 to 14)             |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 182]        | 125.4 (111.6 to 140.8)    |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 192]        | 5192.9 (4101.3 to 6575.1) |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 364]        | 2610.2 (2085.3 to 3267.2) |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Vaccine response rate for neutralising antibodies

|                                                                                |                                                   |
|--------------------------------------------------------------------------------|---------------------------------------------------|
| End point title                                                                | Vaccine response rate for neutralising antibodies |
| End point description:<br>Vaccine response rate against Flu A/Ind/05/05 (H5N1) |                                                   |
| End point type                                                                 | Secondary                                         |

End point timeframe:

At Day 42, Day 182, Day 192 and Day 364

| End point values                 | GSK1562902A Group    |  |  |  |
|----------------------------------|----------------------|--|--|--|
| Subject group type               | Subject analysis set |  |  |  |
| Number of subjects analysed      | 83                   |  |  |  |
| Units: Subjects                  |                      |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 42]  | 62                   |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 182] | 69                   |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 192] | 72                   |  |  |  |
| Flu A/Ind/05/05 (H5N1) [Day 364] | 83                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Vaccine response rate for neutralising antibodies

|                        |                                                       |
|------------------------|-------------------------------------------------------|
| End point title        | Vaccine response rate for neutralising antibodies     |
| End point description: | Vaccine response rate against Flu A/Turk/01/05 (H5N1) |
| End point type         | Secondary                                             |
| End point timeframe:   | At Day 182, Day 192 and Day 364                       |

| End point values                     | GSK1562902A Group    |  |  |  |
|--------------------------------------|----------------------|--|--|--|
| Subject group type                   | Subject analysis set |  |  |  |
| Number of subjects analysed          | 83                   |  |  |  |
| Units: Subjects                      |                      |  |  |  |
| Flu A/Turk/01/05 (H5N1) Ab [Day 182] | 58                   |  |  |  |
| Flu A/Turk/01/05 (H5N1) Ab [Day 192] | 72                   |  |  |  |
| Flu A/Turk/01/05 (H5N1) Ab [Day 364] | 83                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Booster vaccine response for neutralising antibodies

|                        |                                                          |
|------------------------|----------------------------------------------------------|
| End point title        | Booster vaccine response for neutralising antibodies     |
| End point description: | Booster vaccine response against Flu A/Turk/01/05 (H5N1) |

|                        |           |
|------------------------|-----------|
| End point type         | Secondary |
| End point timeframe:   |           |
| At Day 192 and Day 364 |           |

|                                   |                      |  |  |  |
|-----------------------------------|----------------------|--|--|--|
| <b>End point values</b>           | GSK1562902A Group    |  |  |  |
| Subject group type                | Subject analysis set |  |  |  |
| Number of subjects analysed       | 79                   |  |  |  |
| Units: Subjects                   |                      |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 192] | 69                   |  |  |  |
| Flu A/Turk/01/05 (H5N1) [Day 364] | 76                   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with any and Grade 3 solicited local symptoms

|                 |                                                                  |
|-----------------|------------------------------------------------------------------|
| End point title | Number of subjects with any and Grade 3 solicited local symptoms |
|-----------------|------------------------------------------------------------------|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During a 7-day follow-up period, i.e. day of vaccination and 6 subsequent days after each vaccination on Day 0, Day 21 and Day 182

| End point values            | GSK1562902A<br>6<12 M Group | GSK1562902A<br>12<24 M Group | GSK1562902A<br>24<36 M Group | GSK1562902A<br>Group |
|-----------------------------|-----------------------------|------------------------------|------------------------------|----------------------|
| Subject group type          | Reporting group             | Reporting group              | Reporting group              | Subject analysis set |
| Number of subjects analysed | 46                          | 33                           | 33                           | 112                  |
| Units: Subjects             |                             |                              |                              |                      |
| Any Pain Dose 1             | 14                          | 5                            | 13                           | 32                   |
| Grade 3 Pain Dose 1         | 2                           | 0                            | 1                            | 3                    |
| Any Redness Dose 1          | 2                           | 0                            | 2                            | 4                    |
| Grade 3 Redness Dose 1      | 0                           | 0                            | 0                            | 0                    |
| Any Swelling Dose 1         | 1                           | 1                            | 1                            | 3                    |
| Grade 3 Swelling Dose 1     | 0                           | 0                            | 0                            | 0                    |
| Any Pain Dose 2             | 10                          | 13                           | 14                           | 37                   |
| Grade 3 Pain Dose 2         | 0                           | 0                            | 1                            | 1                    |
| Any Redness Dose 2          | 3                           | 2                            | 1                            | 6                    |
| Grade 3 Redness Dose 2      | 0                           | 0                            | 0                            | 0                    |
| Any Swelling Dose 2         | 2                           | 2                            | 0                            | 4                    |
| Grade 3 Swelling Dose 2     | 0                           | 0                            | 0                            | 0                    |
| Any Pain Dose 3             | 20                          | 15                           | 18                           | 53                   |

|                               |    |    |    |    |
|-------------------------------|----|----|----|----|
| Grade 3 Pain Dose 3           | 3  | 1  | 3  | 7  |
| Any Redness Dose 3            | 11 | 5  | 2  | 18 |
| Grade 3 Redness Dose 3        | 0  | 0  | 0  | 0  |
| Any Swelling Dose 3           | 5  | 5  | 1  | 11 |
| Grade 3 Swelling Dose 3       | 0  | 0  | 0  | 0  |
| Any Pain Across doses         | 26 | 19 | 21 | 66 |
| Grade 3 Pain Across doses     | 4  | 1  | 5  | 10 |
| Any Redness Across doses      | 13 | 6  | 3  | 22 |
| Grade 3 Redness Across doses  | 0  | 0  | 0  | 0  |
| Any Swelling Across doses     | 6  | 6  | 1  | 13 |
| Grade 3 Swelling Across doses | 0  | 0  | 0  | 0  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with any, Grade 3 and related solicited general symptoms

|                 |                                                                             |
|-----------------|-----------------------------------------------------------------------------|
| End point title | Number of subjects with any, Grade 3 and related solicited general symptoms |
|-----------------|-----------------------------------------------------------------------------|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During a 7-day follow-up period, i.e. day of vaccination and 6 subsequent days after each vaccination on Day 0, Day 21 and Day 182

| End point values                      | GSK1562902A<br>6<12 M Group | GSK1562902A<br>12<24 M Group | GSK1562902A<br>24<36 M Group | GSK1562902A<br>Group |
|---------------------------------------|-----------------------------|------------------------------|------------------------------|----------------------|
| Subject group type                    | Reporting group             | Reporting group              | Reporting group              | Subject analysis set |
| Number of subjects analysed           | 46                          | 33                           | 33                           | 112                  |
| Units: Subjects                       |                             |                              |                              |                      |
| Any Diarrhoea/vomiting Dose 1         | 10                          | 6                            | 3                            | 19                   |
| Grade 3 Diarrhoea/vomiting Dose 1     | 1                           | 1                            | 0                            | 2                    |
| Related Diarrhoea/vomiting Dose 1     | 6                           | 1                            | 2                            | 9                    |
| Any Drowsiness Dose 1                 | 10                          | 9                            | 5                            | 24                   |
| Grade 3 Drowsiness Dose 1             | 1                           | 0                            | 0                            | 1                    |
| Related Drowsiness Dose 1             | 8                           | 7                            | 5                            | 20                   |
| Any Irritability/fussiness Dose 1     | 21                          | 14                           | 9                            | 44                   |
| Grade 3 Irritability/fussiness Dose 1 | 3                           | 0                            | 0                            | 3                    |
| Related Irritability/fussiness Dose 1 | 19                          | 10                           | 8                            | 37                   |
| Any Loss of appetite Dose 1           | 9                           | 12                           | 6                            | 27                   |
| Grade 3 Loss of appetite Dose 1       | 0                           | 1                            | 0                            | 1                    |
| Related Loss of appetite Dose 1       | 5                           | 8                            | 5                            | 18                   |
| Any Fever (Axillary) Dose 1           | 4                           | 6                            | 4                            | 14                   |
| Grade 3 Fever (Axillary) Dose 1       | 0                           | 2                            | 0                            | 2                    |
| Related Fever (Axillary) Dose 1       | 3                           | 5                            | 3                            | 11                   |

|                                             |    |    |    |    |
|---------------------------------------------|----|----|----|----|
| Any Diarrhoea/vomiting Dose 2               | 8  | 3  | 2  | 13 |
| Grade 3 Diarrhoea/vomiting Dose 2           | 0  | 0  | 0  | 0  |
| Related Diarrhoea/vomiting Dose 2           | 7  | 2  | 1  | 10 |
| Any Drowsiness Dose 2                       | 8  | 12 | 7  | 27 |
| Grade 3 Drowsiness Dose 2                   | 1  | 1  | 1  | 3  |
| Related Drowsiness Dose 2                   | 8  | 10 | 7  | 25 |
| Any Irritability/fussiness Dose 2           | 14 | 17 | 10 | 41 |
| Grade 3 Irritability/fussiness Dose 2       | 1  | 3  | 0  | 4  |
| Related Irritability/fussiness Dose 2       | 13 | 15 | 10 | 38 |
| Any Loss of appetite Dose 2                 | 8  | 6  | 9  | 23 |
| Grade 3 Loss of appetite Dose 2             | 0  | 1  | 0  | 1  |
| Related Loss of appetite Dose 2             | 8  | 5  | 8  | 21 |
| Any Fever (Axillary) Dose 2                 | 14 | 12 | 10 | 36 |
| Grade 3 Fever (Axillary) Dose 2             | 2  | 3  | 1  | 6  |
| Related Fever (Axillary) Dose 2             | 14 | 12 | 10 | 36 |
| Any Diarrhoea/vomiting Dose 3               | 10 | 3  | 3  | 16 |
| Grade 3 Diarrhoea/vomiting Dose 3           | 1  | 0  | 0  | 1  |
| Related Diarrhoea/vomiting Dose 3           | 9  | 2  | 1  | 12 |
| Any Drowsiness Dose 3                       | 16 | 6  | 10 | 32 |
| Grade 3 Drowsiness Dose 3                   | 2  | 0  | 1  | 3  |
| Related Drowsiness Dose 3                   | 16 | 6  | 7  | 29 |
| Any Irritability/fussiness Dose 3           | 28 | 15 | 11 | 54 |
| Grade 3 Irritability/fussiness Dose 3       | 7  | 0  | 2  | 9  |
| Related Irritability/fussiness Dose 3       | 26 | 15 | 10 | 51 |
| Any Loss of appetite Dose 3                 | 16 | 12 | 9  | 37 |
| Grade 3 Loss of appetite Dose 3             | 2  | 0  | 2  | 4  |
| Related Loss of appetite Dose 3             | 15 | 12 | 7  | 34 |
| Any Fever (Axillary) Dose 3                 | 20 | 15 | 19 | 54 |
| Grade 3 Fever (Axillary) Dose 3             | 3  | 5  | 3  | 11 |
| Related Fever (Axillary) Dose 3             | 19 | 15 | 18 | 52 |
| Any Diarrhoea/vomiting Across doses         | 17 | 11 | 7  | 35 |
| Grade 3 Diarrhoea/vomiting Across doses     | 1  | 1  | 0  | 2  |
| Related Diarrhoea/vomiting Across doses     | 14 | 5  | 3  | 22 |
| Any Drowsiness Across doses                 | 22 | 18 | 12 | 52 |
| Grade 3 Drowsiness Across doses             | 3  | 1  | 2  | 6  |
| Related Drowsiness Across doses             | 21 | 17 | 12 | 50 |
| Any Irritability/fussiness Across doses     | 35 | 23 | 15 | 73 |
| Grade 3 Irritability/fussiness Across doses | 10 | 3  | 2  | 15 |
| Related Irritability/fussiness Across doses | 35 | 23 | 14 | 72 |
| Any Loss of appetite Across doses           | 22 | 18 | 14 | 54 |
| Grade 3 Loss of appetite Across doses       | 2  | 2  | 2  | 6  |
| Related Loss of appetite Across doses       | 19 | 17 | 14 | 50 |
| Any Fever (Axillary) Across doses           | 29 | 19 | 21 | 69 |
| Grade 3 Fever (Axillary) Across doses       | 5  | 8  | 4  | 17 |
| Related Fever (Axillary) Across doses       | 28 | 19 | 20 | 67 |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with medically-attended events (MAEs)

|                 |                                                          |
|-----------------|----------------------------------------------------------|
| End point title | Number of subjects with medically-attended events (MAEs) |
|-----------------|----------------------------------------------------------|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the entire study period

| End point values            | GSK1562902A<br>6<12 M Group | GSK1562902A<br>12<24 M<br>Group | GSK1562902A<br>24<36 M<br>Group | GSK1562902A<br>Group |
|-----------------------------|-----------------------------|---------------------------------|---------------------------------|----------------------|
| Subject group type          | Reporting group             | Reporting group                 | Reporting group                 | Subject analysis set |
| Number of subjects analysed | 46                          | 34                              | 33                              | 113                  |
| Units: Subjects             |                             |                                 |                                 |                      |
| Any MAE(s)                  | 29                          | 19                              | 20                              | 68                   |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with potential immune-mediated disease (pIMDs)

|                 |                                                                   |
|-----------------|-------------------------------------------------------------------|
| End point title | Number of subjects with potential immune-mediated disease (pIMDs) |
|-----------------|-------------------------------------------------------------------|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the entire study period

| End point values            | GSK1562902A<br>6<12 M Group | GSK1562902A<br>12<24 M<br>Group | GSK1562902A<br>24<36 M<br>Group | GSK1562902A<br>Group |
|-----------------------------|-----------------------------|---------------------------------|---------------------------------|----------------------|
| Subject group type          | Reporting group             | Reporting group                 | Reporting group                 | Subject analysis set |
| Number of subjects analysed | 46                          | 34                              | 33                              | 113                  |
| Units: Subjects             |                             |                                 |                                 |                      |
| Any pIMDs                   | 0                           | 0                               | 0                               | 0                    |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with unsolicited adverse events (AEs)

|                                                         |                                                          |
|---------------------------------------------------------|----------------------------------------------------------|
| End point title                                         | Number of subjects with unsolicited adverse events (AEs) |
| End point description:                                  |                                                          |
| End point type                                          | Secondary                                                |
| End point timeframe:                                    |                                                          |
| During a 21 day follow-up period after each vaccination |                                                          |

| End point values            | GSK1562902A<br>6<12 M Group | GSK1562902A<br>12<24 M<br>Group | GSK1562902A<br>24<36 M<br>Group | GSK1562902A<br>Group |
|-----------------------------|-----------------------------|---------------------------------|---------------------------------|----------------------|
| Subject group type          | Reporting group             | Reporting group                 | Reporting group                 | Subject analysis set |
| Number of subjects analysed | 46                          | 34                              | 33                              | 113                  |
| Units: Subjects             |                             |                                 |                                 |                      |
| Any AE(s)                   | 29                          | 19                              | 24                              | 72                   |
| Grade 3 AE(s)               | 5                           | 3                               | 2                               | 10                   |
| Related AE(s)               | 13                          | 5                               | 7                               | 25                   |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with unsolicited adverse events (AEs)

|                                                      |                                                          |
|------------------------------------------------------|----------------------------------------------------------|
| End point title                                      | Number of subjects with unsolicited adverse events (AEs) |
| End point description:                               |                                                          |
| End point type                                       | Secondary                                                |
| End point timeframe:                                 |                                                          |
| Up to Day 84 follow-up period after each vaccination |                                                          |

| End point values            | GSK1562902A<br>6<12 M Group | GSK1562902A<br>12<24 M<br>Group | GSK1562902A<br>24<36 M<br>Group | GSK1562902A<br>Group |
|-----------------------------|-----------------------------|---------------------------------|---------------------------------|----------------------|
| Subject group type          | Reporting group             | Reporting group                 | Reporting group                 | Subject analysis set |
| Number of subjects analysed | 46                          | 34                              | 33                              | 113                  |
| Units: Subjects             |                             |                                 |                                 |                      |
| Any AE(s)                   | 32                          | 23                              | 22                              | 77                   |
| Grade 3 AE(s)               | 4                           | 4                               | 2                               | 10                   |
| Related AE(s)               | 9                           | 3                               | 6                               | 18                   |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with serious adverse events (SAEs)

|                 |                                                       |
|-----------------|-------------------------------------------------------|
| End point title | Number of subjects with serious adverse events (SAEs) |
|-----------------|-------------------------------------------------------|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the entire study period

| End point values            | GSK1562902A<br>6<12 M Group | GSK1562902A<br>12<24 M<br>Group | GSK1562902A<br>24<36 M<br>Group | GSK1562902A<br>Group |
|-----------------------------|-----------------------------|---------------------------------|---------------------------------|----------------------|
| Subject group type          | Reporting group             | Reporting group                 | Reporting group                 | Subject analysis set |
| Number of subjects analysed | 46                          | 34                              | 33                              | 113                  |
| Units: Subjects             |                             |                                 |                                 |                      |
| SAEs                        | 5                           | 4                               | 0                               | 9                    |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 15.1 |
|--------------------|------|

### Reporting groups

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | GSK1562902A 6<12 M Group |
|-----------------------|--------------------------|

Reporting group description: -

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | GSK1562902A 12<24 M Group |
|-----------------------|---------------------------|

Reporting group description: -

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | GSK1562902A 24<36 M Group |
|-----------------------|---------------------------|

Reporting group description: -

| <b>Serious adverse events</b>                     | GSK1562902A 6<12 M Group | GSK1562902A 12<24 M Group | GSK1562902A 24<36 M Group |
|---------------------------------------------------|--------------------------|---------------------------|---------------------------|
| Total subjects affected by serious adverse events |                          |                           |                           |
| subjects affected / exposed                       | 5 / 46 (10.87%)          | 4 / 34 (11.76%)           | 0 / 33 (0.00%)            |
| number of deaths (all causes)                     | 0                        | 0                         | 0                         |
| number of deaths resulting from adverse events    | 0                        | 0                         | 0                         |
| Injury, poisoning and procedural complications    |                          |                           |                           |
| Burns second degree                               |                          |                           |                           |
| subjects affected / exposed                       | 0 / 46 (0.00%)           | 1 / 34 (2.94%)            | 0 / 33 (0.00%)            |
| occurrences causally related to treatment / all   | 0 / 0                    | 0 / 1                     | 0 / 0                     |
| deaths causally related to treatment / all        | 0 / 0                    | 0 / 0                     | 0 / 0                     |
| Gastrointestinal disorders                        |                          |                           |                           |
| Diarrhoea                                         |                          |                           |                           |
| subjects affected / exposed                       | 0 / 46 (0.00%)           | 1 / 34 (2.94%)            | 0 / 33 (0.00%)            |
| occurrences causally related to treatment / all   | 0 / 0                    | 0 / 1                     | 0 / 0                     |
| deaths causally related to treatment / all        | 0 / 0                    | 0 / 0                     | 0 / 0                     |
| Respiratory, thoracic and mediastinal disorders   |                          |                           |                           |
| Asthma                                            |                          |                           |                           |
| subjects affected / exposed                       | 2 / 46 (4.35%)           | 0 / 34 (0.00%)            | 0 / 33 (0.00%)            |
| occurrences causally related to treatment / all   | 0 / 2                    | 0 / 0                     | 0 / 0                     |
| deaths causally related to treatment / all        | 0 / 0                    | 0 / 0                     | 0 / 0                     |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Wheezing                                        |                |                |                |
| subjects affected / exposed                     | 1 / 46 (2.17%) | 0 / 34 (0.00%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Upper respiratory tract infection               |                |                |                |
| subjects affected / exposed                     | 1 / 46 (2.17%) | 2 / 34 (5.88%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 2          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Bronchiolitis                                   |                |                |                |
| subjects affected / exposed                     | 1 / 46 (2.17%) | 1 / 34 (2.94%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastritis viral                                 |                |                |                |
| subjects affected / exposed                     | 0 / 46 (0.00%) | 1 / 34 (2.94%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastroenteritis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 46 (0.00%) | 1 / 34 (2.94%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastroenteritis rotavirus                       |                |                |                |
| subjects affected / exposed                     | 1 / 46 (2.17%) | 0 / 34 (0.00%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastroenteritis viral                           |                |                |                |
| subjects affected / exposed                     | 0 / 46 (0.00%) | 1 / 34 (2.94%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Lobar pneumonia                                 |                |                |                |
| subjects affected / exposed                     | 0 / 46 (0.00%) | 1 / 34 (2.94%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 46 (2.17%) | 0 / 34 (0.00%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Dehydration                                     |                |                |                |
| subjects affected / exposed                     | 0 / 46 (0.00%) | 2 / 34 (5.88%) | 0 / 33 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 2          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                           | GSK1562902A 6<12 M Group | GSK1562902A 12<24 M Group | GSK1562902A 24<36 M Group |
|-------------------------------------------------------------|--------------------------|---------------------------|---------------------------|
| Total subjects affected by non-serious adverse events       |                          |                           |                           |
| subjects affected / exposed                                 | 35 / 46 (76.09%)         | 23 / 34 (67.65%)          | 24 / 33 (72.73%)          |
| Investigations                                              |                          |                           |                           |
| Body temperature increased (Day 0-20 following vaccination) |                          |                           |                           |
| subjects affected / exposed                                 | 1 / 46 (2.17%)           | 1 / 34 (2.94%)            | 0 / 33 (0.00%)            |
| occurrences (all)                                           | 1                        | 1                         | 0                         |
| General disorders and administration site conditions        |                          |                           |                           |
| Pain                                                        |                          |                           |                           |
| alternative assessment type: Systematic                     |                          |                           |                           |
| subjects affected / exposed <sup>[1]</sup>                  | 26 / 46 (56.52%)         | 19 / 33 (57.58%)          | 21 / 33 (63.64%)          |
| occurrences (all)                                           | 26                       | 19                        | 21                        |
| Redness                                                     |                          |                           |                           |
| alternative assessment type: Systematic                     |                          |                           |                           |
| subjects affected / exposed <sup>[2]</sup>                  | 13 / 46 (28.26%)         | 6 / 33 (18.18%)           | 3 / 33 (9.09%)            |
| occurrences (all)                                           | 13                       | 6                         | 3                         |
| Swelling                                                    |                          |                           |                           |
| alternative assessment type: Systematic                     |                          |                           |                           |
| subjects affected / exposed <sup>[3]</sup>                  | 6 / 46 (13.04%)          | 6 / 33 (18.18%)           | 1 / 33 (3.03%)            |
| occurrences (all)                                           | 6                        | 6                         | 1                         |
| Diarrhoea/vomiting                                          |                          |                           |                           |
| alternative assessment type: Systematic                     |                          |                           |                           |

|                                               |                  |                  |                  |
|-----------------------------------------------|------------------|------------------|------------------|
| subjects affected / exposed <sup>[4]</sup>    | 17 / 46 (36.96%) | 11 / 33 (33.33%) | 7 / 33 (21.21%)  |
| occurrences (all)                             | 17               | 11               | 7                |
| Drowsiness                                    |                  |                  |                  |
| alternative assessment type:<br>Systematic    |                  |                  |                  |
| subjects affected / exposed <sup>[5]</sup>    | 22 / 46 (47.83%) | 18 / 33 (54.55%) | 12 / 33 (36.36%) |
| occurrences (all)                             | 22               | 18               | 12               |
| Irritability/fussiness                        |                  |                  |                  |
| alternative assessment type:<br>Systematic    |                  |                  |                  |
| subjects affected / exposed <sup>[6]</sup>    | 35 / 46 (76.09%) | 23 / 33 (69.70%) | 15 / 33 (45.45%) |
| occurrences (all)                             | 35               | 23               | 15               |
| Loss of appetite                              |                  |                  |                  |
| alternative assessment type:<br>Systematic    |                  |                  |                  |
| subjects affected / exposed <sup>[7]</sup>    | 22 / 46 (47.83%) | 18 / 33 (54.55%) | 14 / 33 (42.42%) |
| occurrences (all)                             | 22               | 18               | 14               |
| Fever (Axillary)                              |                  |                  |                  |
| alternative assessment type:<br>Systematic    |                  |                  |                  |
| subjects affected / exposed <sup>[8]</sup>    | 29 / 46 (63.04%) | 19 / 33 (57.58%) | 21 / 33 (63.64%) |
| occurrences (all)                             | 29               | 19               | 21               |
| Pyrexia (Day 0-20 following<br>vaccination)   |                  |                  |                  |
| subjects affected / exposed                   | 3 / 46 (6.52%)   | 3 / 34 (8.82%)   | 5 / 33 (15.15%)  |
| occurrences (all)                             | 3                | 3                | 5                |
| Pyrexia (Day 0-84 following<br>vaccination)   |                  |                  |                  |
| subjects affected / exposed                   | 6 / 46 (13.04%)  | 4 / 34 (11.76%)  | 4 / 33 (12.12%)  |
| occurrences (all)                             | 6                | 4                | 4                |
| Gastrointestinal disorders                    |                  |                  |                  |
| Vomiting (Day 0-20 following<br>vaccination)  |                  |                  |                  |
| subjects affected / exposed                   | 0 / 46 (0.00%)   | 2 / 34 (5.88%)   | 4 / 33 (12.12%)  |
| occurrences (all)                             | 0                | 2                | 4                |
| Teething (Day 0-20 following<br>vaccination)  |                  |                  |                  |
| subjects affected / exposed                   | 4 / 46 (8.70%)   | 1 / 34 (2.94%)   | 0 / 33 (0.00%)   |
| occurrences (all)                             | 4                | 1                | 0                |
| Diarrhoea (Day 0-20 following<br>vaccination) |                  |                  |                  |

|                                                                                                           |                        |                      |                     |
|-----------------------------------------------------------------------------------------------------------|------------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                                          | 0 / 46 (0.00%)<br>0    | 1 / 34 (2.94%)<br>1  | 2 / 33 (6.06%)<br>2 |
| Vomiting (Day 0-84 following<br>vaccination)<br>subjects affected / exposed<br>occurrences (all)          | 2 / 46 (4.35%)<br>2    | 3 / 34 (8.82%)<br>3  | 1 / 33 (3.03%)<br>1 |
| Teething (Day 0-84 following<br>vaccination)<br>subjects affected / exposed<br>occurrences (all)          | 4 / 46 (8.70%)<br>4    | 1 / 34 (2.94%)<br>1  | 0 / 33 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal<br>disorders                                                        |                        |                      |                     |
| Cough (Day 0-20 following<br>vaccination)<br>subjects affected / exposed<br>occurrences (all)             | 8 / 46 (17.39%)<br>8   | 5 / 34 (14.71%)<br>5 | 2 / 33 (6.06%)<br>2 |
| Rhinorrhoea (Day 0-20 following<br>vaccination)<br>subjects affected / exposed<br>occurrences (all)       | 10 / 46 (21.74%)<br>10 | 2 / 34 (5.88%)<br>2  | 2 / 33 (6.06%)<br>2 |
| Wheezing (Day 0-20 following<br>vaccination)<br>subjects affected / exposed<br>occurrences (all)          | 0 / 46 (0.00%)<br>0    | 2 / 34 (5.88%)<br>2  | 0 / 33 (0.00%)<br>0 |
| Cough (Day 0-84 following<br>vaccination)<br>subjects affected / exposed<br>occurrences (all)             | 7 / 46 (15.22%)<br>7   | 6 / 34 (17.65%)<br>6 | 2 / 33 (6.06%)<br>2 |
| Rhinorrhoea (Day 0-84 following<br>vaccination)<br>subjects affected / exposed<br>occurrences (all)       | 6 / 46 (13.04%)<br>6   | 1 / 34 (2.94%)<br>1  | 2 / 33 (6.06%)<br>2 |
| Skin and subcutaneous tissue disorders                                                                    |                        |                      |                     |
| Urticaria (Day 0-20 following<br>vaccination)<br>subjects affected / exposed<br>occurrences (all)         | 0 / 46 (0.00%)<br>0    | 0 / 34 (0.00%)<br>0  | 3 / 33 (9.09%)<br>3 |
| Dermatitis diaper (Day 0-20<br>following vaccination)<br>subjects affected / exposed<br>occurrences (all) | 0 / 46 (0.00%)<br>0    | 2 / 34 (5.88%)<br>2  | 0 / 33 (0.00%)<br>0 |
| Eczema (Day 0-20 following                                                                                |                        |                      |                     |

|                                                                    |                 |                 |                  |
|--------------------------------------------------------------------|-----------------|-----------------|------------------|
| vaccination)                                                       |                 |                 |                  |
| subjects affected / exposed                                        | 0 / 46 (0.00%)  | 2 / 34 (5.88%)  | 0 / 33 (0.00%)   |
| occurrences (all)                                                  | 0               | 2               | 0                |
| Rash (Day 0-20 following vaccination)                              |                 |                 |                  |
| subjects affected / exposed                                        | 3 / 46 (6.52%)  | 0 / 34 (0.00%)  | 1 / 33 (3.03%)   |
| occurrences (all)                                                  | 3               | 0               | 1                |
| Dermatitis diaper (Day 0-84 following vaccination)                 |                 |                 |                  |
| subjects affected / exposed                                        | 0 / 46 (0.00%)  | 3 / 34 (8.82%)  | 0 / 33 (0.00%)   |
| occurrences (all)                                                  | 0               | 3               | 0                |
| Eczema (Day 0-84 following vaccination)                            |                 |                 |                  |
| subjects affected / exposed                                        | 1 / 46 (2.17%)  | 3 / 34 (8.82%)  | 0 / 33 (0.00%)   |
| occurrences (all)                                                  | 1               | 3               | 0                |
| Infections and infestations                                        |                 |                 |                  |
| Upper respiratory tract infection (Day 0-20 following vaccination) |                 |                 |                  |
| subjects affected / exposed                                        | 7 / 46 (15.22%) | 5 / 34 (14.71%) | 11 / 33 (33.33%) |
| occurrences (all)                                                  | 7               | 5               | 11               |
| Nasopharyngitis (Day 0-20 following vaccination)                   |                 |                 |                  |
| subjects affected / exposed                                        | 2 / 46 (4.35%)  | 4 / 34 (11.76%) | 2 / 33 (6.06%)   |
| occurrences (all)                                                  | 2               | 4               | 2                |
| Rhinitis (Day 0-20 following vaccination)                          |                 |                 |                  |
| subjects affected / exposed                                        | 4 / 46 (8.70%)  | 0 / 34 (0.00%)  | 2 / 33 (6.06%)   |
| occurrences (all)                                                  | 4               | 0               | 2                |
| Upper respiratory tract infection (Day 0-84 following vaccination) |                 |                 |                  |
| subjects affected / exposed                                        | 9 / 46 (19.57%) | 4 / 34 (11.76%) | 11 / 33 (33.33%) |
| occurrences (all)                                                  | 9               | 4               | 11               |
| Nasopharyngitis (Day 0-84 following vaccination)                   |                 |                 |                  |
| subjects affected / exposed                                        | 2 / 46 (4.35%)  | 5 / 34 (14.71%) | 2 / 33 (6.06%)   |
| occurrences (all)                                                  | 2               | 5               | 2                |
| Rhinitis (Day 0-84 following vaccination)                          |                 |                 |                  |
| subjects affected / exposed                                        | 5 / 46 (10.87%) | 1 / 34 (2.94%)  | 2 / 33 (6.06%)   |
| occurrences (all)                                                  | 5               | 1               | 2                |

---

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 24 January 2011  | <p>Amendment 1</p> <p>The former version of the protocol was published in two versions, due to a technical problem. The first version contained errors in the tables of intensity (Table 15). This version was submitted in Singapore. The second version contained errors in the vaccine tables (Tables 7 and 10), where commas were left out in the volumes. This version was submitted in Australia.</p> <p>This Amendment is based on the latter version of the final protocol. Therefore, track changes on Table 15 will not be found in the amendment, although a difference exists with the version submitted in Singapore. The changes have been brought to the tables as explained under Section 8.2.2.2.1.</p> <p>Additional changes have been brought to clarify the contents of the vials and vaccine doses.</p> |
| 16 June 2011     | <p>Amendment 2</p> <p>The protocol was amended to exclude subjects who had a past medical history of infection with a H5N1 virus or vaccination with a H5N1 vaccine. Exclusion criteria were updated accordingly. In addition, procedures for collection of medically-attended adverse events between Day 203 and Day 364 have been clarified.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 04 November 2011 | <p>Amendment 3</p> <p>With Amendment 3, the protocol was adjusted to document that the age stratification ratio of 2:1:1 for children 6 to 11 months, 12 to 23 months, and 24 to 35 months of age, respectively, will not be maintained due to recruitment difficulties. The overall subjects enrolment goal will not change.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported